Lilly, Food and Drug Administration

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients ...
Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.
Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...